Corporate Member Update: Merck- Keytruda® and LENVIMA® Update
Corporate Member Update: Merck- Keytruda® and LENVIMA® Update
KEYTRUDA® (pembrolizumab) and LENVIMA(® (lenvatinib)
September, 2021
Information about KEYTRUDA(R) (pembrolizumab) and LENVIMA(R) (lenvatinib)
Merck announces that KEYTRUDA® (pembrolizumab), in combination with LENVIMA® (lenvatinib), has been approved by the FDA for first-line treatment of adult patients with advanced
renal cell carcinoma (RCC).
To read the full press release, click here!
